130 results on '"Rampal, Raajit"'
Search Results
2. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
3. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
4. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
5. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
6. Epo-IGF1R cross talk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm
7. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis
8. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation
9. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
10. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression
11. Can molecular insights guide treatment of AML evolved from MPNs?
12. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
13. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
14. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
15. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
16. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
17. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
18. Survival following allogeneic transplant in patients with myelofibrosis
19. Clinical developments in epigenetic-directed therapies in acute myeloid leukemia
20. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
21. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
22. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
23. Oral idasanutlin in patients with polycythemia vera
24. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis
25. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
26. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study
27. MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis
28. MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study
29. Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis
30. High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis
31. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
32. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance
33. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
34. Moving toward disease modification in polycythemia vera
35. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis
36. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
37. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms
38. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
39. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
40. MPN-136 Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
41. MPN-153 A Phase 1b Trial of DISC-0974, an Antihemojuvelin Antibody, in Participants With Myelofibrosis and Anemia
42. Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With Pacritinib in the United States
43. MPN-386 Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With Pacritinib in the United States
44. MPN-135 Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
45. AML-385 A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
46. Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
47. Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
48. A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Participants With Myelofibrosis and Anemia
49. A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
50. Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.